This finding confirms PA as a potential anticancer therapeutic in NSCLC cells through targeting CD133 to block the PI3K/AKT/mTOR and EMT pathways (Figure 7) [49,50,51]. Here, MTOR is linked to non-small cell lung carcinoma.